As drug makers scramble over the biosimilar market, Boehringer Ingelheim has reportedly decided to focus exclusively on the U.S., a nascent, but particularly large opportunity for many pharmaceutical companies.

The decision is rooted in its efforts to sell a biosimilar version of the Humira rheumatoid arthritis medicine made by AbbVie (ABBV). Several other drug makers — Amgen (AMGN), Mylan (MYL), Biogen (BIIB), and Novartis (NVS) — have settled patent litigation in the U.S. with AbbVie. In doing so, these companies won the right to market their biosimilar versions in Europe this fall and in the U.S. in 2023.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I wonder whether one solution to this stringing out of patent applications for a given drug is to require that all patent applications related to the development and manufacture of a given drug be filed at the same time. New, later patents could be issued only if there was a change in the manufacturing process and the patent would be for that change.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy